Literature DB >> 22188361

Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins.

Andrey Khrunin1, Feodosia Ivanova, Alexey Moisseev, Denis Khokhrin, Yuliya Sleptsova, Vera Gorbunova, Svetlana Limborska.   

Abstract

AIM: There is a substantial difference between Asians and Caucasians in their reaction to platinum drugs. To determine whether population-related genomics contribute to differences in patient outcomes, pharmacogenomic relevance of polymorphisms in some genes, the protein activities of which may affect aspects of cisplatin metabolism, were evaluated. PATIENTS &
METHODS: Nineteen polymorphisms in ten genes were tested for correlations with the efficacy and toxicity of a cisplatin-cyclophosphamide regimen in Yakut and Russian patients with ovarian cancer.
RESULTS: The CYP2E1 7632T>A polymorphism was associated with progression-free survival (p = 0.015) in Yakuts. In Russians, progression-free survival was correlated with the GSTP1 Ile105Val polymorphism (p = 0.004). Yakut patients with the GSTT1-null genotype had a higher risk for nephrotoxicity. By contrast, in the Russian group, nephrotoxicity was more frequent among patients with heterozygous ERCC1 genotypes. Severe emesis in Yakuts was independently associated with two polymorphisms in the CYP2E1 gene but in Russians, it was more common in patients with the GSTT1-null genotype. Differences in genotypic correlations with anemia were also observed.
CONCLUSION: Significant differences in genotype distribution between Russian and Yakut women were observed for ten of the 19 polymorphisms, but none of them seemed to be a clear casual candidate and further studies involving more markers are required.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22188361     DOI: 10.2217/pgs.11.140

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  19 in total

1.  Genetic variability of ERCC1 genes in NER pathway influences the treatment outcome of gastric cancer.

Authors:  Yu Bai; Lei Wang; Guangjun Li; Xiangjie Fang; Yan Li; Shujuan Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.

Authors:  J-H Deng; J Deng; D-H Shi; X-N Ouyang; P-G Niu
Journal:  Clin Transl Oncol       Date:  2015-06-02       Impact factor: 3.405

3.  Genetic variation of pharmacogenomic VIP variants in the Chinese Li population: an updated research.

Authors:  Shuangyu Yang; Xia Dou; Zhen Wang; Wenjie Zhang; Kefan Ding; Wenting Meng; Haiyue Li; Jianfeng Liu; Yuanwei Liu; Tianbo Jin
Journal:  Mol Genet Genomics       Date:  2022-02-11       Impact factor: 3.291

Review 4.  Cisplatin nephrotoxicity: new insights and therapeutic implications.

Authors:  Chengyuan Tang; Man J Livingston; Robert Safirstein; Zheng Dong
Journal:  Nat Rev Nephrol       Date:  2022-10-13       Impact factor: 42.439

5.  Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.

Authors:  Deolinda Pereira; Joana Assis; Mónica Gomes; Augusto Nogueira; Rui Medeiros
Journal:  Eur J Clin Pharmacol       Date:  2016-01-23       Impact factor: 2.953

6.  Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array.

Authors:  Sourav Kalra; Raman Preet Kaur; Abhilash Ludhiadch; Gowhar Shafi; Rajesh Vashista; Raj Kumar; Anjana Munshi
Journal:  Eur J Clin Pharmacol       Date:  2018-06-24       Impact factor: 2.953

Review 7.  Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities.

Authors:  Matthew R Trendowski; Omar El Charif; Paul C Dinh; Lois B Travis; M Eileen Dolan
Journal:  Clin Cancer Res       Date:  2018-10-10       Impact factor: 12.531

8.  Allele Frequencies of the Epidermal Growth Factor Receptors Polymorphism R521K in Colorectal Cancer Patients and Healthy Subjects Indicate a Risk-Reducing Effect of K521 in Syrian Population.

Authors:  Ola Haj Mustafa; Abdul Rezzak Hamzeh; Lina Ghabreau; Nizar Akil; Ala-Eddin Almoustafa; Amal Alachkar
Journal:  N Am J Med Sci       Date:  2013-03

9.  Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer.

Authors:  Sandrina Lambrechts; Diether Lambrechts; Evelyn Despierre; Els Van Nieuwenhuysen; Dominiek Smeets; Philip R Debruyne; Vincent Renard; Philippe Vroman; Daisy Luyten; Patrick Neven; Frédéric Amant; Karin Leunen; Ignace Vergote
Journal:  BMC Pharmacol Toxicol       Date:  2015-02-27       Impact factor: 2.483

10.  ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis.

Authors:  Yuqiang Zhang; Sufen Cao; Chunyu Zhuang; Jiacheng Chen; Xiaojing Chen; Hong Sun; Shengying Lin; Bailang Lin
Journal:  J Ovarian Res       Date:  2021-06-21       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.